BofA lowered the firm’s price target on Avantor (AVTR) to $16 from $20 and keeps a Buy rating on the shares following a Q1 sales miss and FY25 guidance cut. With shares trading meaningfully lower, the firm thinks the reason for the selloff is a general view that Avantor’s outlook still has some risk, both from the updated organic growth view and tariff exposure. Despite the firm’s concerns, it doesn’t think “things are as dire as they appear” and it argues the valuation remains “compelling,” the analyst added.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTR:
- Avantor: Overcoming Challenges with Strategic Leadership and Attractive Valuation
- Avantor price target lowered to $15 from $18 at Barclays
- Avantor’s Hold Rating: Challenges in Bioprocess and Lab Consumables Amid Low Valuation
- Avantor downgraded to Hold from Buy at TD Cowen
- Avantor’s Hold Rating: Navigating Revenue Misses, Bioprocess Challenges, and Leadership Uncertainty